You have full text access to this OnlineOpen article

CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome

  1. Stefan Heinrichs1,†,
  2. Jason N. Berman1,2,†,
  3. Taylor M. Ortiz1,
  4. Steven M. Kornblau3,
  5. Donna S. Neuberg4,
  6. Elihu H. Estey3,
  7. A. Thomas Look1

Article first published online: 2 JUN 2005

DOI: 10.1111/j.1365-2141.2005.05555.x

Issue

British Journal of Haematology

British Journal of Haematology

Volume 130, Issue 1, pages 83–86, July 2005

Additional Information

How to Cite

Heinrichs, S., Berman, J. N., Ortiz, T. M., Kornblau, S. M., Neuberg, D. S., Estey, E. H. and Thomas Look, A. (2005), CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome. British Journal of Haematology, 130: 83–86. doi: 10.1111/j.1365-2141.2005.05555.x

Author Information

  1. 1

    Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

  2. 2

    Department of Pediatric Oncology, Children's Hospital, Boston, MA

  3. 3

    Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

  4. 4

    Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

  1. †

    These authors contributed equally to this study.

*A. Thomas Look, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Mayer 630, 44 Binney Street, Boston, MA 02115, USA. E-mail: thomas_look@dfci.harvard.edu

Publication History

  1. Issue published online: 2 JUN 2005
  2. Article first published online: 2 JUN 2005
  3. Received 2 March 2005; accepted for publication 1 April 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

Keywords:

  • myelodysplastic syndrome;
  • CD34;
  • HOX

Summary

Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34+ BM cells at median levels 3·1-fold higher than in CD34− cells from the same patient and at median levels 4·3-fold higher than in CD34+ cells from healthy donors. These results indicate that CD34+ cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.

View Full Article (HTML) Get PDF (81K)